News
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification in sepsis and other acute infections, today announces the launch of its
Peptomyc Appoints Selwyn Ho to its Board of Directors
Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered,
Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (https://www.nature.com/articles/s41591-024-02805-1), demonstrating the unique potential
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection testing at the Point-of-Care, announced a national distribution agreement with Cardinal
binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform
binx health announced today it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the
